All In Biotech

Drug Trial Radar · NCT05907304

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations

An Open-label Study to Assess the Safety and Efficacy of Naporafenib (ERAS-254) Administered With Trametinib in Previously Treated Patients With Locally Advanced Unresectable or Metastatic Solid Tumor Malignancies With RAS Q61X Mutations

Last checked: Nov 20, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

86

Actual

Start

Aug 17, 2023

Primary completion

Jul 1, 2025

Study completion Dec 2026

Sponsor

Lead sponsor
Erasca, Inc.Industry
Sponsor type
Industry
First posted
Jun 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors * To evaluate the safety and tolerability of naporafenib administered with trametinib in patients with RAS Q61X solid tumors * To characterize the pharmacokinetic (PK) profile of naporafenib and trametinib when administered to patients with RAS Q61X solid tumors

Conditions

  • Advanced or Metastatic Solid Tumors

Interventions

  • NaporafenibDrug

    Naporafenib (ERAS-254) 200 mg twice daily (BID) of an experimental Pan-Raf inhibitor

  • TrametinibDrug

    Trametinib is an FDA approved anticancer medication that targets MEK1 and MEK2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumorsTime frame: Assessed up to 24 months from time of first dose

Locations

29 sites in 5 countries. Site status is shown where the registry gives one.

  • University of California, San Francisco

    San Francisco, California

  • Yale Cancer Center

    New Haven, Connecticut

  • Florida Cancer Specialists - Sarasota

    Sarasota, Florida

  • Florida Cancer Specialists - St. Petersburg

    St. Petersburg, Florida

  • Emory University School of Medicine

    Atlanta, Georgia

  • Henry Ford Health System

    Detroit, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • Comprehensive Cancer Center of Nevada (CCCN)

    Las Vegas, Nevada

  • Oregon Health & Science University

    Portland, Oregon

  • SCRI Oncology Partners (formerly Tennessee Oncology)

    Nashville, Tennessee

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Inova Schar Cancer Institute

    Fairfax, Virginia

  • NEXT Virginia

    Fairfax, Virginia

  • University of Wisconsin

    Madison, Wisconsin

  • Linear Clinical Research, LTD

    Perth, Australia

  • Macquarie University

    Macquarie Park, New South Wales, Australia

  • St. Vincent's Hospital

    Melbourne, Victoria, Australia

  • Cross Cancer Institute- Alberta Health Services (AHS)

    Edmonton, Alberta, Canada

  • British Columbia Cancer Agency

    Vancouver, British Columbia, Canada

  • London Regional Cancer Center

    London, Ontario, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • National Cancer Center

    Goyang-si, South Korea

  • Seoul National University Hospital Bundang

    Gyeonggi-do, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • The Catholic University Hospital

    Seoul, South Korea

  • Inje University Haeundae Paik Hospital

    Busan, Busan Gwang'yeogsi, South Korea

  • Samsung Medical Center

    Seoul, Seoul Teugbyeolsi, South Korea

  • Beatson West of Scotland Cancer Center

    Glasgow, United Kingdom

  • Sarah Cannon Research Institute - HCA Healthcare

    City of London, London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.